Breaking News, Financial News

Lilly 4Q08

Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve sales collectively grew 10% to $1.9 billion and accounted for 37% of total sales, compared with 33% in 4Q07.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 4Q Revenues: $5.2 billion (flat) 4Q Loss: $3.6 billion (earnings were $854.4 million in 4Q07) FY Revenues: $20.4 billion (+9%) FY Loss: $2.0 billion (earnings were $3.0 billion FY08) Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve sales collectively grew 10% to $1.9 billion and accounted for 37% of total sales, compared with 33% in 4Q07. Cymbalta sales were $721.2 million (+15%). Humalog sales were $457.9 million (+11%). Alimta sa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters